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Abstract
Background: Advance care planning (ACP) is a process of planning for future health and personal care. A person’s
values and preferences are made known so that they can guide decision making at a future time when that person
cannot make or communicate his or her decisions. This is particularly relevant for people with dementia because
their ability to make decisions progressively deteriorates over time. This study aims to evaluate the cost-effectiveness of
delivering a nationwide ACP program within the Australian primary care setting.
Methods: A decision analytic model was developed to identify the costs and outcomes of an ACP program for people
aged 65+ years who were at risk of developing dementia. Inputs for the model was sourced and estimated from the
literature. The reliability of the results was thoroughly tested in sensitivity analyses.
Results: The results showed that, compared to usual care, a nationwide ACP program for people aged 65+ years who
were at risk of dementia would be cost-effective. However, the results only hold if ACP completion is higher than 50%
and adherence to ACP wishes is above 75%.
Conclusions: A nationwide ACP program in the primary care setting is a cost-effective or cost-saving intervention
compared to usual care in a population at-risk of developing dementia. Cost savings are generated from providing
treatment and care that is consistent with patient preferences, resulting in fewer hospitalisations and less-intensive care
at end-of-life.
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What is already known about the topic?
 Advance care planning (ACP) empowers patients,
with the support of their caregivers, to consider and
communicate their current and future treatment
goals in the context of their own preferences and
values. However, the uptake ACP in older people
and people with dementia remains low.
 Known benefits of ACP include reduced stress and
anxiety for the surviving family members and an
increased likelihood that patient wishes will be
known and respected at end-of-life. Preliminary
research also suggests that ACP may reduce costs or
be cost-neutral at end-of-life.
 Studies estimating the economic impact of ACP are
scarce and no studies have systematically identified
costs and outcomes, or the potential trade-off be-
tween these factors.
What this paper adds?
 This is the first study to use a Markov cohort model
to estimate the cost-effectiveness of a nationwide
ACP program in a primary care setting for people
aged 65+ years who are at risk of dementia.
 This study found that providing an nationwide ACP
intervention in a primary care setting for people
aged 65+ before they develop dementia, in a series
of consultations lasting between 30 and 90 min
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each, is a cost-effective strategy compared to the
current situation (without the nationwide
intervention).
 The study identified three interdependent
determinants of a successful ACP program: uptake
rate, compliance, and end-of-life choices. The cost-
effectiveness cannot be substantiated if high ACP
uptake is accompanied by a low compliance with
ACP, or if end-of-life hospitalisation continues to be
the dominant choice due to a lack of well-supported
alternatives in the community.
Implications for practice, theory or policy
 The study has important implications for the design
and implementation of a national ACP policy, both
in Australia and internationally. It highlighted the
importance of a systematic approach along the
continuum of care and a flexible ACP design to
accommodate different life situations.
Background
Empirical studies show that healthcare costs increase ex-
ponentially at end of life [1–4], but increased spending
may not improve quality of care [5]. In addition, aggres-
sive medical treatment at the end of life may be incon-
sistent with the care preferences of the patient [6] or
prove to be unnecessary [7]. In Australia, approximately
80% of adults will be admitted to hospital in the last year
of their life, with more than 30% spending more than
30 days in hospital, 55% dying in hospital, 12% attending
the intensive care unit and only 24% receiving palliative
care [8].
Advance care planning (ACP) is a process that ex-
plores a person’s values, beliefs and preferences regard-
ing future health and personal care to guide medical
decision making at a future time when that person can
no longer communicate his or her decisions. This
process usually involves the patient, family members,
other important persons and healthcare providers [9].
ACP has been shown to improve the likelihood that doc-
tors and family members will know and comply with the
patient’s wishes [9–11], increase hospice and palliative
care use, decrease inappropriate life-sustaining treat-
ments and hospital admissions, improve patient and
family satisfaction with care, as well as reduce stress,
anxiety and depression in surviving relatives [10, 12–14].
ACP is particularly important in the dementia context
because the cognition and decision-making capacity of
individuals with dementia becomes increasingly limited
as the disease progresses, and ACP becomes the sole ve-
hicle to foster autonomous decision making [15].
Because ACP increases the likelihood that the medical
treatment wishes of the patient will be known and
respected, it also has an impact on the cost of care at
end–of-life. Two recent systematic reviews examining
the effects of ACP on cost of end-of-life care were iden-
tified. Klingler et al. (2015) showed that facilitated ACP
had the potential to reduce net costs of care [16], while
Dixon et al. (2015) found associations between ACP and
healthcare savings for people living with dementia in the
community, and for people living in areas with high
end-of-life care spending [17]. However, the authors did
not systematically identify both costs and outcomes, or
the potential trade-off between these factors.
This study aims to overcome the limitations of past
economic evaluations of ACP. We developed an eco-
nomic model to assess the cost-effectiveness of an ACP
intervention in a cohort of older people (aged 65+ years)
who were at risk of cognitive decline in the context of
the Australian healthcare system. The Markov modelling
technique was used to simulate a decision problem in-
volving risk over time (e.g. progression of dementia),
when the timing of events is important (e.g. introducing
ACP before loss of ability to communicate in people
with moderate to severe dementia) and when important
events may repeat (e.g. treatment or care for episodes of
illness). It can mimic the clinical pathway and allows the
capture of costs and outcomes associated with important
events over time. Markov models have been widely used
in economic evaluations of healthcare interventions to
inform funding decisions.
We hypothesised that a nationwide ACP program de-
livered to an Australian population aged 65+ years who
are at risk of developing dementia would:
(i) increase the rate of ACP completion
(ii)increase the likelihood that end-of-life wishes will be
known and respected, and
(iii)result in more efficient use of healthcare resources
by reducing the use of unnecessary healthcare
interventions near the end of life.
Methods
Overview
A life-time health state transition model was used to
combine data on the healthcare costs and health out-
comes of two scenarios: (i) with a nationwide ACP pro-
gram in the primary care setting, and (ii) current
situation. The study population were adults aged 65+
years. It is known that while dementia is not a normal
part of aging, age itself is the highest risk factor of devel-
oping dementia. Using the Australian health system per-
spective, the key outcome was the incremental cost per
quality-adjusted life year (QALY), which represents the
additional cost of an ACP program per additional QALY
gained (if any) compared with the current situation.
Both costs and outcomes were discounted at 5% in the
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base case and at 2% and 7% in the sensitivity analyses.
The reliability of the results was tested in sensitivity ana-
lyses, which included threshold analyses and second
order probabilistic sensitivity analyses with 5000
replications.
Scenarios
Current situation
The Australian healthcare system does not currently
have a consistent systematic approach to ACP. ACP pro-
grams are provided by some community services, resi-
dential aged care facilities and tertiary hospitals. Some
primary care providers also support individuals to
complete advance care directives (ACDs). Models vary
from employing dedicated ACP facilitators to training
existing clinicians to conduct ACP in addition to their
role; thus, the service quality provided to patients can
also vary. The current uptake of ACP in people aged 65
+ years in Australia does not exceed 15% [9, 18, 19].
Introduction of a nationwide ACP intervention in the
primary care setting
We propose a nationwide primary care program to pro-
vide ACP to people aged 65+ years. The program has a
relatively flexible design so the ACP discussions can be
conducted in various settings (e.g. general practitioners’
offices, nurse-led medical centres, residential care or
homes). Once individuals reach the target age (65 years),
their doctors, nurses or dedicated ACP facilitators will
initiate the ACP discussion by providing relevant mate-
rials and following up for further development, or refer-
ring them to the most suitable settings. It is estimated
that the whole ACP process, from initial discussion to
the completion of an ACD, will be undertaken over two
to four face-to-face consultations. An additional review
of the ACD should occur at critical times, such as when
individuals are diagnosed with dementia or a terminal
illness, or other life-changing circumstances. The ACD
should be shared between the individuals’ families and
the health system (i.e. general practitioners, specialists
and hospitals).
Elements of this proposed intervention were based on
extensive research which indicated that primary care set-
tings are an ideal platform for an ACP program [20, 21],
and that ACP development should involve repeated con-
sultations and discussions with the individuals, their
families and their healthcare providers [11].
Model structure
A life-time Markov cohort model with a one-year cycle
was constructed and analysed in TreeAge Pro 2015 soft-
ware. Five health states were used to account for the de-
velopment and progression of dementia and for end-of-
life (see Fig. 1). Dementia stages include mild, moderate
and severe, based on the Clinical Dementia Rating clas-
sification and previous modelling approaches [22–24].
Older people (aged 65+ years) entered the model and
moved between the various health states according to
dementia progression and general health deterioration.
Both the probabilities of developing dementia and the
mortality risk were age dependent, while the probabil-
ities of disease progression (from mild to moderate, from
moderate to severe) and the preference for end-of-life
hospitalisation were constant over time. Since dementia
is a non-reversible condition, individuals can only move
from mild to moderate to severe, but not the reverse.
Because disease states other than dementia can also re-
sult in loss of capacity, the model dictated that at any
point in time, an individual could fall very ill and move
to end-of-life care before they died.
In the model, an individual could engage in the ACP
process while he/she did not have dementia. This as-
sumption ensured that ACP was commenced well before
the dementia progression limited an individual’s ability
to fully engage in the process of eliciting their prefer-
ences and wishes [25–27]. The ACD, once completed,
would be reviewed when the individual was first diag-
nosed with dementia or another terminal illness. A final
review of the document would occur when the individ-
ual enters the end-of-life period, where the ACD might
be discussed, revised or followed up by the family and
medical professionals.
Data input and resources
Since we focused on the impact of ACP on medical deci-
sions at the end-of-life, both scenarios incorporated an
identical likelihood of dying, risk of illness and develop-
ing dementia, and associated costs. The main differences
related to the coverage of ACP; cost of the ACP pro-
gram; the end-of-life care cost; and quality of life, in-
cluding the disutility associated with the ACP non-
compliance, or unknown preferences of the patients due
to the absence of an ACD or surrogate decision maker.
While most inputs were constant, the risk of developing
Fig. 1 Health state transition diagram
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dementia, all-cause mortality risk and hospitalisation
costs increased with age. For the base case, we conserva-
tively assumed that the quality of life and wellbeing of
individuals would not be reduced when their wishes
(specified in their ACD) were not respected (compared
to the scenario where their wishes were fully respected).
In reality, not having preferences and wishes honoured
is likely to bring distress and lower wellbeing for individ-
uals (represented as disutility in health economics).
To identify relevant evidence to populate the model,
the Medline database and grey literature were searched.
The search strategy used key words (and their combina-
tions) such as advance care plan, advance care directive,
dementia, and Alzheimer’s disease. A manual search of
the references of each identified article of interest was
also completed for further information. Other sources of
information included national epidemiological studies
and costing reports. All costs were calculated in 2015
Australian dollars. Detailed descriptions and assump-
tions of the data and their sources are presented in the
Additional file 1: and the summary in Tables S1 and S2.
Results
The base case results and selected sensitivity analyses
are presented in Table 1 and Fig. 2.
Base case findings
The base case assumed (i) the starting age for having an
ACP was 65 years, and (ii) a 50% uptake rate of ACP
should the program be introduced. The results showed
that over a lifetime, compared to the current situation, a
nationwide ACP program was less costly while achieving
the same QALY outcome. The cost-saving came from
the lower rate of hospital-based end-of-life care for pa-
tients who had an ACP. Patients in both scenarios (ACP
program versus current situation) accrued the same
QALYs because we conservatively assumed no quality of
life difference associated with not having an end-of-life
preference followed (i.e. zero disutility weight) [9, 28,
29]. If any disutility was assumed, ACP became a domin-
ant option: cheaper and more effective.
Sensitivity analyses
Extensive sensitivity analyses, including threshold ana-
lyses, were conducted on the key parameters to assess
the likelihood of ACP remaining cost effective. The re-
sult was highly sensitive to several key parameters (see
Table 1): ACP completion and compliance rates; and
dying choice (hospital versus non-hospital settings). The
probability sensitivity analysis of 5000 Monte Carlo rep-
lications highlighted that there was a 50–50 chance that
a nationwide ACP program would be cost effective (see
Fig. 2) due to high uncertainty around the key
parameters.
Advance care planning completion rate
A breakeven point was identified for the completion rate
in order for ACP to remain cost saving or neutral. Our
model indicated that even at a low coverage (26%), ACP
was still a cost-saving strategy if the majority of
Table 1 Base case results and selected sensitivity analyses
Scenarios Current
situation
ACP
program
Incremental
cost ($)
Conclusion
Base case 6749 6682 −67 Cost effective
Starting age = 75 years (base case = 65 years) 7250 7160 −90 Cost effective
End-of-life non-
hospitalisation cost = 70% hospitalisation cost (base case = 60%)
7194 7216 22 Not cost effective
ACP coverage, with ACP program = 30% (base case = 50%) 6749 6765 −16 Cost effective
ACP compliance rate, with ACP program =
60% (base case = 86%)
6816 6913 97 Not cost effective
Choose to die in hospital, with ACP program = 60% (base case = 15%) 7324 7563 239 Not cost effective
ACP program of 6 visits, excluding revision visits (base case = 4 visits, excluding revision visits) 6749 6754 5 Not cost effective
Abbreviation: ACP advance care planning
Note: We do not present the incremental cost effectiveness ratio (ICER) here because we conservatively assumed zero disutility associated with not having an
end-of-life preference followed, which leads to same QALYs accrued for both scenarios. Instead, incremental costs are presented
Fig. 2 Probabilistic sensitivity analysis (Monte Carlo simulation with
5000 draws and willingness-to-pay of AUD 50,000)
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individuals prefer end-of-life care outside hospitals and
if their wishes are respected.
Compliance rate
Compliance is the likelihood of the ACP being respected
and followed. Our model predicted that if the compli-
ance rate dropped below 75% then the ACP program
was no longer cost effective. Additionally, with a moder-
ate coverage (below 40%) and high hospitalisation rate
for end-of-life care, even a high compliance rate was not
sufficient to make the ACP program a good investment.
End-of-life cost
There is a consensus that hospital-based end-of-life care
is more expensive than the alternatives such as home
care, residential aged care facilities and hospice facilities
[30]. However, little comparative data is available that
quantifies the cost differences, especially for end-of-life
care at home. International studies that are available
might not be directly applicable to the Australian health-
care system due to health system differences [30–32]. In
our base case, we started with an estimate that patients
who did not die in hospital had roughly 40% less costs
than those who died in hospital. The lower the former
cost, the more cost-saving the ACP program would be.
However, if the actual cost for dying outside of hospital
rose to approximately 70% of cost of dying in hospital,
the savings from unnecessary hospitalisation were insuf-
ficient to outweigh the cost of providing ACP.
Place of death
Past research showed that the majority of people would
prefer to receive end-of-life care and die outside of hos-
pital [33], and individuals who participated in ACP were
significantly less likely to die in hospital [33–36]. We
tested this proportion in a threshold analysis and found
that if 60% of patients with an ACP wanted to receive
end-of-life care in hospital, then the ACP program was
no longer cost saving. This proportion was unlikely as
surveys estimate that 60–70% of Australians would pre-
fer to die at home [33, 37].
Cost of ACP
A more comprehensive ACP program might have higher
costs than what is anticipated in our model. It has been
suggested that an effective and systematic approach to
ACP should include personalised discussion about life
values and preferences for end-of-life care [38]. These
discussions will occur over several visits, facilitated by
paid and well-trained facilitators, and with active partici-
pation of informed surrogates. These visits can also be
supported by oral, written and video recorded informa-
tion, which will require more systematic and repeated
training of the facilitators [38]. Another component of a
comprehensive ACP program might include legal re-
quirements for the dissemination of the ACP document
amongst families and medical institutions. Our model
indicated that if the cost per individual ACP reaches
$850 (equivalent to seven visits) then the program is no
longer cost effective. Nonetheless, this scenario is un-
likely because individual ACP has been provided suc-
cessfully in Australia through group information
sessions followed by 1–2 visits by trained ACP facilita-
tors, which costs less than AU$250. At this cost, the
program is more likely to be cost-effective than the base
case scenario.
Discussion
This is the first dementia-specific study to evaluate the
cost-effectiveness of ACP in a simulated population
using the Markov modelling technique. These findings
demonstrate that providing a nationwide ACP interven-
tion comprised of three to four consultations (30–
90 min each) for people aged 65+ years, who are at risk
of dementia, is cost effective, provided that the ACP up-
take and compliance with end-of-life wishes rates are at
least 50% and 75%, respectively. Whilst we acknowledge
that cost savings should not be the main aim of introdu-
cing a wider ACP policy, our model showed that a sec-
ondary positive outcome was the reduction in healthcare
expenditure, making those resources available to other
patients and population health interventions.
In line with the concept that ACP should be initiated
‘earlier rather than later’ in people with dementia, before
the loss of capacity and ability to communicate occurs,
our model indicated cost-effectiveness diminished when
ACP was introduced later in life. This finding is not sur-
prising as ACP discussion may be less feasible with an
individual with moderate or severe dementia. For ex-
ample, a systematic review examining the effectiveness
of conducting ACP in people with dementia found that
the majority of participants did not have the capacity to
complete an ACP discussion in the nursing home setting
and thus had to defer the decision-making responsibility
to surrogates [34].
Our model showed that the economic benefit of a na-
tionwide ACP program was dependent on a moderate
uptake rate and a high compliance rate in an environ-
ment where dying outside hospital was a preferred
choice. We found that an uptake rate as low as 26% was
still cost saving if the majority of individuals preferred
end-of-life care outside hospitals and if their wishes were
respected. It is noted that the ACD is legally binding
under statute legislation throughout most of Australia
and under the Common Law in New South Wales and
Tasmania, thus a high compliance rate (given a
moderate-to-high uptake rate) is warranted. Addition-
ally, if a national ACP program were to be introduced, it
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should contain an education component for both health
care providers and community members to ensure that
they understand that ACP compliance is not optional.
Therefore, a critical consideration here is whether or not
the demand for high quality palliative care services, both
at home and in the hospice setting, can be met and,
therefore, whether or not people’s wishes are feasible at
the end of life.
Dying in hospital facilities and the use of life-
sustaining measures are individual preferences that
should be fully respected. However, delayed end-of-life
decision-making usually leads to unwanted and/or un-
warranted aggressive life-sustaining measures being in-
stigated for those approaching end of life, including
those who are imminently dying. Unwanted heroic mea-
sures have been shown to negatively influence quality of
life in the week before death [37, 39], which may explain
why most people prefer to die at home rather than in
admitted inpatient settings [33]. This may be especially
relevant for people in the advanced stages of dementia
due to the prospect of imminent death, where caring
and comforting, rather than curing, are needed. People
with a preference to die at their residence (e.g. home or
aged care facility) will require their carers and homes to
be sufficiently supported and equipped to provide end-
of-life care. Assessment of the current and potential
risks for emergency and inpatient admission, and formu-
lating a plan of action, may help prevent unwanted hos-
pitalisation when a crisis or other intense situation
occurs.
The ability to fully realise the benefits demonstrated in
the modelling is dependent on accessible high quality
community and palliative care services. Without access
to support at home, it is likely that people at end of life
will end up dying in hospital despite their expressed
wishes. Our model suggested that an additional 15% of
older people would die outside of hospital if this model
of ACP was fully implemented. It is unlikely that current
services would have capacity to care for these additional
people at home and implementing this model of ACP in
Australia would necessarily require an additional invest-
ment in community services by government and/or a re-
alignment of funding from hospital care to community
and residential aged care facilities. It is noted by the
Productivity Commission [37] that approximately 70%
Australians preferred to die at home but less than 10%
were able to do so, and 20% of older people living in
residential aged care facilities died in hospital due to a
lack of palliative care expertise and qualified staff.
A complex multi-faceted ACP intervention is more
likely to increase compliance with individuals’ end-of-life
wishes [11]. The ACP program proposed in our paper is
based on a series of consultations in the primary care
setting, which is often considered an effective setting for
ACP. First, general practitioners and other community-
based health professionals are in an ideal position to fa-
cilitate ACP because they have an ongoing relationship
with the patient and often understand his/her healthcare
needs [20]. It is also recognised that people are more
empowered in primary care than in other healthcare set-
tings [21]. Second, community dwellers are still generally
in good health and more likely to have decision-making
capacity. As noted in Robinson et al. (2012) [34], resi-
dential aged care settings might be too late for starting
the ACP journey as many residents have lost their
decision-making capacity.
Furthermore, recent best-practice recommendations
(Draft Recommendation 4.3 from the Productivity Com-
mission’s Draft Report of June 2017 [37]) suggest the
Australian Government should promote and aim to in-
crease the uptake of ACP in primary care by a) requiring
the general practitioner to introduce the concept of ACP
and b) introducing a new Medicare item number to fund
practice nurses to facilitate ACP. If such initiatives were
implemented nationally we believe the feasibility of
meeting the ACP uptake and compliance rates required
in our model would be met and, thus, increase the likeli-
hood of ACP being a cost-effective intervention in the
primary care setting.
The lack of continuity of care and poor information
sharing between primary and tertiary medical practi-
tioners currently limits the effectiveness of ACP [40].
Technological innovations such as smart phone applica-
tions or digital wrist bracelets are potential vehicles to
disseminate ACP information and documents during an
emergency [38]. The recently-developed electronic
health record in Australia also provides an ideal measure
to carry ACP with the patients regardless of their
location.
Despite using the best available evidence, a number of
assumptions and simplification were necessary in our
model. First, we estimated the age-dependent utility,
mortality and end-of-life hospitalisation costs from the
literature using multivariate regression analyses. Second,
we assumed a constant rate of transition from mild to
moderate to severe dementia, as well as stable prefer-
ences for end-of-life hospitalisation across disease state
and age. We have performed extensive sensitivity ana-
lyses and highlighted influential factors (e.g. compliance
rates and hospitalisation preferences). While these were
strongly grounded on the existing literature, they should
be revisited when new information becomes available.
Lastly, we could only evaluate the ACP program using a
health-system perspective, instead of a societal perspec-
tive. It is known that end-of-life care and medical deci-
sions often impose a heavy burden, represented by
potential productivity loss and a reduction in the mental
and physical health of family and caregivers. While there
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are a large body of qualitative literature highlighting the
burden, our literature search indicated that there were
no reliable quantitative studies that could be used for
this model. Additionally, if the (base case) ACP model
was found to be cost-effective under the health-system
perspective, which ignored the social costs avoided by
family and caregivers if an individual has an ACP, a
model with a social perspective would have a result that
leads to the same cost-effective conclusion. The thresh-
olds for ACP uptake and compliance rates and prefer-
ences for end-of-life hospitalisation, from a social
perspective, would have been lower than those for the
health system perspective.
Conclusion
Our model indicates that a nationwide ACP intervention
in the Australian primary care setting is a cost-effective
option compared to usual care for the older population
at risk of developing dementia. The result is largely
driven by providing treatment and care consistent with
patient ACP preferences, leading to fewer hospitalisa-
tions and less-intensive care at end-of-life. In order to
meet the ACP uptake and compliance rates required in
the model for ACP to be cost-effective, we recommend
the Australian Government supports a national and con-
sistent approach to ACP in the primary care setting.
Australia is ready to take the next step toward respect-
ing end-of-life choices. Taking the initiative and time,
and a positive attitude towards anticipating future sce-
narios seems universal across different parties and stud-
ies. All jurisdictions have developed regulatory and
legislative frameworks to support ACP. There is also
strong support for normalising ACP and promoting it
earlier in life. Raising community awareness of ACP and
adjusting attitudes towards ACP in primary care settings
will enable the existing healthcare infrastructure to ac-
commodate ACP, without a significant paradigm shift in
service models. The ACP, which allows an individual to
expressly state their wishes for end-of-life care, helps
families, caregivers and health professionals to act, as far
as possible, in accordance with the person’s own
expressed and considered wishes and expectations.
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